ADS DIAGNOSTIC LTD.

A D S Diagnostics Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item is to consider and approve the audited financial results for the quarter ended June 30, 2026. The meeting will also address any other business as permitted by the Chairman. The notice is issued in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ADS Diagnostics Ltd's board approved the audited standalone financial results for the quarter and year ended March 31, 2026. The board recommended a dividend of 12%, which is ₹1.20 per share with a face value of ₹10 each, subject to shareholder approval. The Board Meeting commenced at 11:45 a.m. and concluded at 13:32 p.m.

A D S Diagnostics Ltd has announced a meeting of its Board of Directors scheduled for May 29, 2026. The meeting will consider and approve the audited financial results of the company for the quarter ended March 31, 2026, and transact any other business with the Chairman's permission. The meeting will be held at the Registered Office or via Zoom.

ADS Diagnostic Ltd. has announced its unaudited standalone financial results for the quarter ended 31st December, 2025. The company's income from operations stands at Rs. 1,459,013 lacs, a decrease from the previous quarter's Rs. 1,524,450 lacs. The total expenses for the quarter are Rs. 520,42 lacs, with deferred tax charge at Rs. 444. The company's total other comprehensive income after tax is Rs. 1,949 lacs. The company's paid-up equity share capital is Rs. 21,928 lacs and the diluted EPS is Rs. 3.67.

A D S Diagnostics Ltd has announced a Board meeting scheduled on 13th February 2026. The meeting will consider and approve the unaudited financial results of the company for the quarter ended 31st December 2025. Any other businesses that may be placed before the Board will also be considered with the permission of the Chairman.

ADS Diagnostic Ltd, engaged in trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines, has reported its unaudited standalone financial results for the quarter and half year ended 30th September, 2025. The total income for the quarter is Rs. 1,44,5001 lakhs and for the half year is Rs. 1,89,905 lakhs. The profit before tax for the quarter is Rs. 8,160 lakhs and for the half year is Rs. 6,173 lakhs. The net profit after tax for the quarter is Rs. 6,083 lakhs and for the half year is Rs. 4,746 lakhs. The earnings per share (EPS) for the quarter is Rs. 2.47 and for the half year is Rs. 3.45. The cash and cash equivalents as at the end of the half year is Rs. 447,103 lakhs.

ADS Diagnostic Limited has announced its 40th Annual General Meeting (AGM) to be held on Monday, the 29th September, 2025, at 11:30 A.M. through Video Conferencing. The AGM will transact the business of considering and adopting the Audited Financial Statement of the Company for the year ended 31, March, 2025, together with the Reports of the Board of Directors and the Auditors thereon. The AGM will also consider the re-appointment of Dr. Gautam Sehgal as Managing Director for a period of five years.

ADS Diagnostic Ltd, a company engaged in the trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines, has announced its unaudited standalone financial results for the quarter ended June 30, 2025. The Board of Directors reviewed these results in a meeting held on August 12, 2025. The company operates in one reportable segment in accordance with Ind AS 108. The results are prepared in compliance with the Companies (Indian Accounting Standards) Rules, 2015 and other recognized accounting practices. The Audit Committee and the Board of Directors have approved these results.

ADS Diagnostic Ltd has announced its audited financial results for the year ended 31st March 2025. The company reported a net profit of Rs. 1,850.00 and recommended a dividend of 10% per share for the financial year 2024-25. The Board Meeting was held on 30th May 2025 and commenced at 11:30 a.m., concluding at 02:25 p.m.

ADS Diagnostics Ltd, in compliance with Regulation 31(4) of SEBI LORD Regulation, has declared that the members of the Promoter and Promoter Group, including Persons acting in concert, have not made any encumbrance of shares, directly or indirectly during the financial year ended March 31, 2025. This declaration has been made four times in the disclosure, indicating a strong commitment to transparency and shareholder protection.